<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>260127</rcn>
  <id>101145335</id>
  <acronym>OVACell</acronym>
  <teaser><![CDATA[Ovarian cancer represents the most lethal gynecological cancer and one of the deadliest cancers in women globally, it affected more than 80 0000 women worldwide in 2022 and killed 207000 the same year, 25000 only in Europe. A woman's risk of getting ovarian cancer during her...]]></teaser>
  <objective><![CDATA[Ovarian cancer represents the most lethal gynecological cancer and one of the deadliest cancers in women globally, it affected more than 80 0000 women worldwide in 2022 and killed 207000 the same year, 25000 only in Europe. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 78. 
Due to the non-specific nature of the symptoms, it is hard to early detect ovarian cancer, and there is currently a lack of effective screening tools for an early diagnosis. Consequently, 75% of patients are diagnosed at an advanced stage leading to poor outcomes, and strongly reducing their chances for survival: only 30-40% five years after diagnosis. 
Even though several treatments are currently approved for ovarian cancer, they present several limitations and fail to meet the high medical need. Indeed, 2/3 of patients do not respond to available treatments or relapse after 1st- and 2nd-line treatment.
ErVaccine aims to provide an innovative solution by developing a new generation of TCR-T cell therapy targeting non-conventional antigens. With its advanced proprietary bioinformatic platform, ErVaccine successfully identified antigens derived from human endogenous retroviruses (HERVs) that exhibit abnormal expression exclusively in cancer cells and shared by a high proportion of patients. From this work, the company developed TCR-OV1, a TCRT-cell therapy with a demonstrated efficacy profile in in vitro and ovarian cancer animal models. We expect no major safety concern as we did not observe any toxicity in our preclinical models and based on the specific HERV expression in the tumors. 
Now, ErVaccine wants to accelerate the development of its solution by scaling-up its small-scale manufacturing process and demonstrating in humans the efficacy and safety of TCR-OV1. 
TCR-OV1 has the potential to be a transformative therapy for ovarian cancer, being the first safe and efficient TCR-T cell therapy in this indication.]]></objective>
  <title>Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer</title>
  <keywords>Ovarian cancer, immunotherapy, T cell therapy, bioproduction, women health, novel tumor antigens</keywords>
  <totalCost>3650067.5</totalCost>
  <ecMaxContribution>2499999</ecMaxContribution>
  <startDate>2024-03-01</startDate>
  <endDate>2025-08-31</endDate>
  <ecSignatureDate>2024-02-06</ecSignatureDate>
  <duration>18</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101145335</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-08-04 12:52:04</sourceUpdateDate>
  <contentCreationDate readOnly="true">2024-02-13 14:53:01</contentCreationDate>
  <contentUpdateDate>2025-08-04 12:52:04</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-09-19 14:48:35</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <rcn>449798</rcn>
        <id>449798-targeting-human-endogenous-retroviruses-for-cancer-immunotherapy</id>
        <title>Targeting human endogenous retroviruses for cancer immunotherapy</title>
        <contentUpdateDate>2024-06-06 16:54:00</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode readOnly="true">/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode readOnly="true">/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="2499999" terminated="false" sme="true" netEcContribution="2499999" totalCost="3650067.5" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1987133</rcn>
        <id>883238739</id>
        <vatNumber>FR92877916213</vatNumber>
        <legalName>ERVIMMUNE</legalName>
        <address>
          <street>CENTRE LEON BERARD 28 RUE LAENNEC</street>
          <city>LYON</city>
          <postalCode>69008</postalCode>
          <country>FR</country>
          <geolocation>45.7481616,4.8556858678641275</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Rhône</name>
              <rcn>1465355</rcn>
              <nutsCode>FRK26</nutsCode>
              <parents>
                <region>
                  <name>Rhône-Alpes</name>
                  <rcn>1464966</rcn>
                  <nutsCode>FRK2</nutsCode>
                  <parents>
                    <region>
                      <name>Auvergne-Rhône-Alpes</name>
                      <rcn>1464964</rcn>
                      <nutsCode>FRK</nutsCode>
                      <parents>
                        <region>
                          <name>France</name>
                          <rcn>258902568</rcn>
                          <nutsCode>FR</nutsCode>
                          <euCode>FR</euCode>
                          <isoCode>FR</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>France</name>
              <rcn>258902568</rcn>
              <nutsCode>FR</nutsCode>
              <euCode>FR</euCode>
              <isoCode>FR</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>707276</rcn>
        <id>HORIZON_HORIZON-EIC-2023-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2023-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open 2023</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1245615</rcn>
        <id>101145335_1_DELIVHORIZON</id>
        <title>Press releases</title>
        <description>Press release on the obtention of the EIC Accelerator</description>
        <sourceUpdateDate>2025-01-20 23:12:08</sourceUpdateDate>
        <contentUpdateDate>2025-01-27 10:04:38</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/deliverable</code>
              <title>Project deliverable</title>
              <description>Result: Project deliverables</description>
              <displayCode readOnly="true">/Project deliverable</displayCode>
            </category>
            <category classification="deliverableType" type="isDeliveredAs">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/DEC</code>
              <title>Websites, patent fillings, videos etc.</title>
              <displayCode readOnly="true">/Websites, patent fillings, videos etc.</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
          <associations>
            <webLink source="corda" type="projectDeliverable">
              <language>en</language>
              <availableLanguages readOnly="true">en</availableLanguages>
              <defaultLanguage>en</defaultLanguage>
              <id>7bb80e714fc934079eabdaefcf39d0f4</id>
              <physUrl><![CDATA[https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e51082ecb1&appId=PPGMS]]></physUrl>
            </webLink>
          </associations>
        </relations>
      </result>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1260596</rcn>
        <id>101145335_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - OVACell (Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer)</title>
        <teaser>ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T cell-based therapies. The major step is the choice of a target specifically expressed by cancer cells and shared between patients. Human endogenous retroviruses (HERVs) answered to these two...</teaser>
        <description>periodic</description>
        <sourceUpdateDate>2025-02-24 14:51:33</sourceUpdateDate>
        <contentUpdateDate>2025-02-24 14:51:33</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1243807</rcn>
        <id>101145335_112517_PUBLIHORIZON</id>
        <title>HERV-derived epitopes represent new targets for T-cell based immunotherapies in ovarian cancer</title>
        <details>
          <authors>Paola Bonaventura, Olivier Tabone, Yann Estornes, Audrey Page, Virginie Mutez, Marie Delles, Sarah Moran, Clarisse Dubois, Marjorie Lacourrege, Dina Tawfik, Ema Etchegaray, Adrian Valente, Rasha E. Boulos, Gabriel Jimenez Dominguez, Nicolas Chuvin, Nicolas Gadot, Qing Wang, Jenny Valladeau-Guilemond, Stéphane Depil</authors>
          <journalNumber/>
          <journalTitle/>
          <publishedPages/>
          <publishedYear>2024</publishedYear>
          <publisher>biorxiv</publisher>
        </details>
        <sourceUpdateDate>2025-01-13 11:08:17</sourceUpdateDate>
        <contentUpdateDate>2025-01-20 08:12:44</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode readOnly="true">/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/OTHER</code>
              <title>Other</title>
              <displayCode readOnly="true">/Other</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode readOnly="true">/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155/643</code>
        <title>immunotherapy</title>
        <displayCode readOnly="true">/medical and health sciences/basic medicine/immunology/immunotherapy</displayCode>
      </category>
      <category weight="40" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="40" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-EIC-ACC-BF</code>
        <title>HORIZON EIC Accelerator Blended Finance</title>
        <description>HORIZON EIC Accelerator Blended Finance</description>
        <displayCode readOnly="true">/HORIZON EIC Accelerator Blended Finance</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
